Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.

AIMS The effect of resistant hypertension on outcomes in patients with atherothrombotic disease is currently unknown. Accordingly, we sought to determine the prevalence and outcomes of resistant hypertension in stable hypertensive outpatients with subclinical or established atherothombotic disease enrolled in the international Reduction of Atherothrombosis for Continued Health (REACH) registry. METHODS AND RESULTS Resistant hypertension was defined as a blood pressure ≥140/90 mmHg at baseline (≥130/80 mmHg if diabetes/renal insufficiency) with the use of ≥3 antihypertensive medications, including a diuretic. The primary outcome was a composite of cardiovascular death, myocardial infarction, or stroke at 4 years. A total of 53 530 hypertensive patients were included. The prevalence of resistant hypertension was 12.7%; 6.2% on 3 antihypertensive agents, 4.6% on 4 agents, and 1.9% on ≥5 agents (mean: 4.7 ± 0.8). In addition to a diuretic, these patients were being treated mostly with ACE-inhibitors/angiotensin receptor blockers (90.1%), beta-blockers (67.0%), and calcium channel blockers (50.8%). Patients with resistant hypertension had a higher risk of the primary endpoint on multivariable analysis [hazard ratio (HR) 1.11, 95% confidence interval (CI) 1.02-1.20; P = 0.017], including an increased non-fatal stroke risk (HR: 1.26; 95% CI: 1.10-1.45; P = 0.0008). Hospitalizations due to congestive heart failure were higher (P < 0.0001). Patients on ≥5 agents had a higher adjusted risk for the primary endpoint when compared with those on ≤3 agents (P = 0.03). CONCLUSION The presence of resistant hypertension identifies a subgroup of patients with hypertension and atherothrombosis who are at heightened risk for adverse long-term outcomes.

[1]  V. Falk,et al.  Regurgitation after Edwards SAPIEN valve implantation: truly paravalvular or 'supra-skirtal'? , 2013, European heart journal.

[2]  Deepak L. Bhatt,et al.  Catheter‐Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN‐3 Trial , 2012, Clinical cardiology.

[3]  W. Elliott,et al.  What is the prevalence of resistant hypertension in the United States? , 2012, Current opinion in cardiology.

[4]  Heather M. Tavel,et al.  Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.

[5]  Deepak L. Bhatt,et al.  Abstract 15957: Prospective Assessment of the Relationship Between Use of Evidence-Based Secondary Prevention Therapies and Long-Term (4-Year) Clinical Outcomes in Stable Outpatients With Established Atherothrombotic Disease: Insights from the International REduction of Atherothrombosis for Continue , 2011 .

[6]  B. Egan,et al.  Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008 , 2011, Circulation.

[7]  G. Bakris,et al.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. , 2011, Journal of the American College of Cardiology.

[8]  Stephen D. Persell.  Prevalence of Resistant Hypertension in the United States, 2003–2008 , 2011, Hypertension.

[9]  J. Banegas,et al.  Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring , 2011, Hypertension.

[10]  T. Marwick,et al.  Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. , 2011, Journal of the American College of Cardiology.

[11]  L. Ruilope,et al.  Renal function and target organ damage in hypertension. , 2011, European heart journal.

[12]  Deepak L. Bhatt,et al.  Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials. , 2011, American heart journal.

[13]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[14]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[15]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[16]  Deepak L. Bhatt,et al.  Advancing the care of cardiac patients using registry data: going where randomized clinical trials dare not. , 2010, JAMA.

[17]  H. Krum,et al.  New Therapeutic Approaches to Resistant Hypertension , 2010, Current hypertension reports.

[18]  W. J. Elliott,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2010 .

[19]  A. Dominiczak,et al.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. , 2009, Journal of hypertension.

[20]  B. Wiens,et al.  A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[21]  Deepak L. Bhatt,et al.  Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry , 2009, European heart journal.

[22]  Giuseppe Mancia,et al.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document , 2009, Blood pressure.

[23]  G. Bakris,et al.  Resistant hypertension: an overview of evaluation and treatment. , 2008, Journal of the American College of Cardiology.

[24]  D. Goff,et al.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.

[25]  Daniel W. Jones,et al.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.

[26]  H. Volk,et al.  Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study , 2008, The Lancet.

[27]  M. Cheitlin,et al.  Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study , 2008 .

[28]  B. Gersh.  One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis , 2008 .

[29]  Renata Cifkova,et al.  Erratum: Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology (Journal of Hypertension (2007) 25, (1105-1187)) , 2007 .

[30]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[31]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[32]  J. Manson,et al.  Prospective Study of , 2007 .

[33]  Deepak L. Bhatt,et al.  The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. , 2006, American heart journal.

[34]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[35]  F. Fricke.  Cost-effectiveness analysis (CEA) health economic point of view. , 2006, American heart journal.

[36]  F. Cuccurullo,et al.  Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. , 2005, American journal of hypertension.

[37]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[38]  Steven Hawken,et al.  Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .

[39]  G. De Backer,et al.  Blood pressure is insufficiently controlled in European patients with established coronary heart disease , 2003, Journal of hypertension.

[40]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[41]  H. Hense,et al.  Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. , 2003, JAMA.

[42]  J. Staessen,et al.  Outcome beyond blood pressure control? , 2003, European heart journal.

[43]  G. Parati,et al.  Task Force IV: Clinical use of ambulatory blood pressure monitoring , 1999 .

[44]  G. Parati,et al.  Task force IV: Clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on Ambulatory Blood Pressure Monitoring. , 1999, Blood pressure monitoring.

[45]  L. Ruilope,et al.  Prognostic value of ambulatory blood pressure monitoring in refractory hypertension , 1997 .